Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on New Jersey Health Reporter.
Press releases published on June 23, 2025
Eyenovia Announces Closing of $50 Million Private Placement, Successful Accumulation of More Than One Million HYPE Tokens, and Update on its Optejet Development Program
GlobeNewswire
·
June 23, 2025
The significant HYPE token position, acquired at an average price of approximately $34 per token, makes Eyenovia the first Nasdaq listed company to run a validator on Hyperliquid FDA registration of the Optejet User Filled Device (UFD) on track for …
BioStem Technologies Completes Enrollment in Clinical Trial Evaluating BioREtain® Amnion Chorion for Treatment of Diabetic Foot Ulcers
GlobeNewswire
·
June 23, 2025
Head-to-head study comparing BioREtain®- processed Amnion Chorion (BR-AC) allograft to standard of care initiated in Q4 2024 to demonstrate healing superiority Topline results and full data analysis expected in Q4 2025 POMPANO BEACH, Fla., June 23, 2025 ( …
Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Bolster U.S. Biodefense Supply
GlobeNewswire
·
June 23, 2025
GAITHERSBURG, Md., June 23, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has been awarded a $62.4 million contract modification from the Administration for Strategic Preparedness and Response (ASPR), a division of the …
NKGen Biotech Announces International and U.S. Expansion of Phase 1/2a Troculeucel Alzheimer’s Trial with Activation of Clinical Sites in Canada and Florida
GlobeNewswire
·
June 23, 2025
SANTA ANA, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer …
Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer
GlobeNewswire
·
June 23, 2025
NEEDHAM, Mass., June 23, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today …
Firefly Neuroscience to be Added to the Russell Microcap® Index
GlobeNewswire
·
June 23, 2025
– Comes less than a year after listing on Nasdaq – KENMORE, N.Y., June 23, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that …
Ashvattha Therapeutics Reports the Ability to Tune Nanomedicines to Image Neuroinflammation in Multiple Sclerosis Patients and Tumor Associated Macrophages in Cancer at SNMMI Annual Meeting
GlobeNewswire
·
June 23, 2025
Novel nanomedicine radiotracer crosses blood brain barrier in patients with neuroinflammation Tumor macrophage radiotracer achieves 41.6% peak tumor uptake in preclinical studies REDWOOD CITY, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Ashvattha …
Ajay Dhankhar joins Smith+Nephew as Chief Corporate Development & Strategy Officer
GlobeNewswire
·
June 23, 2025
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces the appointment of Ajay Dhankhar, PhD, as Chief Corporate Development …
MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development
GlobeNewswire
·
June 23, 2025
CARMEL, Ind., June 23, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic …
Chiesi Global Rare Diseases Awards Research Grants to Advance Innovation in Lysosomal Diseases
GlobeNewswire
·
June 23, 2025
PARMA, Italy, June 23, 2025 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, today announced the recipients of its "Find For …
Optime Care Partners with Tilde Sciences as Exclusive Specialty Pharmacy Provider for Vecamyl
GlobeNewswire
·
June 23, 2025
ST. LOUIS, June 23, 2025 (GLOBE NEWSWIRE) -- Optime Care, AscellaHealth’s Specialty Pharmacy, is pleased to announce an expanded partnership with Tilde Sciences LLC (“Tilde”), effective June 23, 2025. Under this arrangement, Optime Care will serve as the …
Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA)
GlobeNewswire
·
June 23, 2025
Oral presentation highlighted the post-hoc analysis during the “Interventions to Prevent Hypoglycemia: Bench to Bedside” session Treatment with sotagliflozin resulted in no increased risk and a reduction in hypoglycemia events, particularly in patients …
ORYZON Announces Submission of Phase III Protocol to FDA to Initiate PORTICO-2 Trial of Vafidemstat in Borderline Personality Disorder (BPD) Patients
GlobeNewswire
·
June 23, 2025
PORTICO-2 designed to validate vafidemstat’s efficacy in reducing aggression in BPD patients Primary endpoint: STAXI-2 Trait Anger (patient-reported) Key secondary endpoint: Overt Aggression Scale-Modified (OAS-M) (clinician-rated) Additional secondary …
RAPT Therapeutics Names Two Industry Veterans to its Board of Directors
GlobeNewswire
·
June 23, 2025
SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living …
AnswersNow CEO and Founder Jeff Beck Named EY Entrepreneur of the Year®2025 Mid-Atlantic Award Winner
GlobeNewswire
·
June 23, 2025
RICHMOND, Va., June 23, 2025 (GLOBE NEWSWIRE) -- AnswersNow, the leader in virtual Applied Behavioral Analysis (ABA) therapy, today announced that Ernst …
Kestra Medical Technologies Announces Inclusion in the Russell 2000® and Russell 3000® Indexes
GlobeNewswire
·
June 23, 2025
KIRKLAND, Wash., June 23, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced that the company will be added to the Russell 3000® Index, with automatic …
Grace Therapeutics Announces 2025 Fiscal Year-End Results, Provides Business Update
GlobeNewswire
·
June 23, 2025
Held Type C meeting with FDA on Planned New Drug Application (NDA) Submission, Including Clinical, Non-clinical, and Chemistry, Manufacturing, and Control (CMC) Requirements NDA On Track for Submission to FDA in First Half of Calendar 2025 NDA to be …
Immutep Announces Positive Update from Phase I Study of IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases
GlobeNewswire
·
June 23, 2025
Initial pharmacological data from placebo-controlled, double-blind Phase I study shows significant T cell suppression and a favourable safety profile at dosing level of 0.9 mg/kg The substantial reduction in T cell activity highlights the potential …
Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering
GlobeNewswire
·
June 23, 2025
HOUSTON, June 23, 2025 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) (the “Company”) today announced that it has entered into a definitive agreement with certain investors (the “SPA”) for the purchase and sale of an aggregate of 610,399 …
Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program
GlobeNewswire
·
June 23, 2025
RESEARCH TRIANGLE PARK, N.C., June 23, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule …